Vega Investment Solutions Purchases Shares of 3,671 IQVIA Holdings Inc. $IQV

Posted by Brian Himes on Aug 25th, 2026

Vega Investment Solutions acquired a new position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,671 shares of the medical research company’s stock, valued at approximately $709,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Korea Investment CORP acquired a new position in shares of IQVIA during the second quarter worth approximately $13,918,000. BlackRock Inc. acquired a new stake in shares of IQVIA in the second quarter worth $2,811,292,000. Concurrent Investment Advisors LLC increased its position in IQVIA by 36.0% during the fourth quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock worth $2,693,000 after acquiring an additional 3,161 shares during the period. Focus Partners Advisor Solutions LLC acquired a new position in IQVIA during the 2nd quarter valued at $976,000. Finally, Nippon Life Global Investors Americas Inc. raised its stake in IQVIA by 36.6% during the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company’s stock valued at $17,898,000 after purchasing an additional 21,270 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. BMO Capital Markets raised their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Royal Bank Of Canada increased their target price on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Robert W. Baird lifted their target price on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. TD Cowen boosted their price target on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, Mizuho upped their price target on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

Get Our Latest Research Report on IQVIA

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is currently owned by insiders.

IQVIA Stock Up 0.2%

Shares of IQV opened at $260.30 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a 50-day moving average price of $214.97 and a two-hundred day moving average price of $187.62. The stock has a market cap of $42.85 billion, a price-to-earnings ratio of 32.30, a P/E/G ratio of 2.21 and a beta of 1.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $261.88.

IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period in the prior year, the company posted $2.81 EPS. The company’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has approved a share buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

IQVIA Company Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.